Thermo Fisher Scientific Q3 GAAP operating income climbs 17% to $2.26 billion

• Thermo Fisher Scientific’s third-quarter 2026 GAAP diluted earnings per share rose 9% year over year to $4.64.
• Revenue climbed 9% to $12.14 billion, while GAAP operating income increased 17% to $2.26 billion.
• The company completed its microbiology business divestiture and launched Precure with Mayo Clinic to advance earlier disease detection.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Thermo Fisher Scientific Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261020833836) on October 21, 2026, and is solely responsible for the information contained therein.